Clinical Rheumatology

, Volume 17, Issue 6, pp 465–467 | Cite as

Scleromyositis: a scleroderma/polymyositis overlap syndrome

  • S. Jablonska
  • M. Blaszcyk
Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992;71:321–35.Google Scholar
  2. 2.
    Blaszczyk M, Jablonska S, Szymanska-Jagiello W, Jarzabek-Chorzelska M, Chorzelski T, Abdelaziz H. Childhood scleromyositis: an overlap syndrome associated with PM-Scl antibody. Pediatr Dermatol 1991;8:1–8PubMedGoogle Scholar
  3. 3.
    Hausmanowa-Petrusewicz I, Blaszczyk M, Kowalska E, Rowiñska K, Zakrzewska B, Drac H, Jablonska M. Neuromuscular studies in scleromyositis. Acta Cardiomiologica 1994;6:99–110.Google Scholar
  4. 4.
    Reichlin M, Maddison PJ, Targoff I, Bunch T, Arnett FC, Sharp GC, Treadwell E. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984;4:40–4.PubMedGoogle Scholar
  5. 5.
    Ge Q, Wu Y, James JA, Targoff IN. Epitope analysis of the major reactive region of the 100 kD protein of PM-Scl autoantigen. Arthritis Rheum 1996;39:1588–95.PubMedGoogle Scholar
  6. 6.
    Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75 kD acidic protein of the nucleolar complex. J Exp Med 1991;173:941–52.PubMedGoogle Scholar
  7. 7.
    Bluthner M, Bautz EK, Bautz FA. Mapping of epitopes recognized by PM/Scl autoantibodies with gene-fragment phage display libraries. J Immunol Methods 1996;198:187–98.PubMedGoogle Scholar
  8. 8.
    Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211–7.PubMedGoogle Scholar
  9. 9.
    Schnitz W, Taylor-Albert E, Targoff IN, Reichlin M, Scofield RH. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 1996;23:1729–33.PubMedGoogle Scholar
  10. 10.
    Alarcon-Segovia D, Cardiel MM. Comparison between three diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989;16:328–34.PubMedGoogle Scholar
  11. 11.
    Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 1996;23:2055–62.PubMedGoogle Scholar
  12. 12.
    Maddison PJ, Jablonksa S. Overlap syndromes. In: Karter L, Baart de la Faille H, editors. Multi-systemic autoimmune diseases. Amsterdam: Elsevier, 1995:227–40.Google Scholar
  13. 13.
    Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Miller FW, Jarzabek-Chorzelska M, Targoff IN, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:1257–66.PubMedGoogle Scholar
  14. 14.
    Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Humma M. Autoantibodies to small nuclear and cytoplasmic ribonucleo-proteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 1992;35:449–56.PubMedGoogle Scholar
  15. 15.
    Isern RA, Yaneva M, Weiner E, Parke A, Rothfield N, Dantzker D, et al. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 1992;93:307–12.PubMedGoogle Scholar
  16. 16.
    Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune disease and probes for cell biology. Adv Immunol 1989;44:93–151.PubMedGoogle Scholar
  17. 17.
    Targoff IN. Laboratory manifestations of polymyositis/dermatomyositis. Clin Dermatol 1988;6:76–92.PubMedGoogle Scholar
  18. 18.
    Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992;18:455–82.PubMedGoogle Scholar
  19. 19.
    Love LA, Miller FW. Noninfectious environmental agents associated with myopathies. Curr Opin Rheumatol 1993;5:712–8.PubMedGoogle Scholar
  20. 20.
    Hausmanova-Petrusewicz I, Blaszczyk M, Jablonska S. Coexistence of scleromyositis associated with PM-Scl antibody and myasthenia. Neuromusc Disord 1995;5:145–7.PubMedGoogle Scholar
  21. 21.
    Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993;100:116S-23S.PubMedGoogle Scholar
  22. 22.
    Miller FW. Myositis specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993;270:1846–9.PubMedGoogle Scholar
  23. 23.
    Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360–74.PubMedGoogle Scholar
  24. 24.
    Jablonska S, Chorzelski TP, Blaszczyk M, Jarzabek-Chorzelska M, Kumar V, Beutner EH. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 1993;10:457–72.Google Scholar
  25. 25.
    Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Banker BQ, editors. Myology. New York: McGraw-Hill, 1994.Google Scholar

Copyright information

© Clinical Rheumatology 1998

Authors and Affiliations

  • S. Jablonska
    • 1
  • M. Blaszcyk
    • 1
  1. 1.Department of DermatologyWarsaw School of MedicineWarsawPoland

Personalised recommendations